688298 东方生物
已收盘 12-11 15:00:00
资讯
新帖
简况
每周股票复盘:东方生物(688298)召开临时股东会并选举独董
证券之星 · 11-23
每周股票复盘:东方生物(688298)召开临时股东会并选举独董
东方生物(688298)披露选举独立董事并调整专门委员会议案获股东会通过,11月20日股价下跌1.58%
证券之星 · 11-20
东方生物(688298)披露选举独立董事并调整专门委员会议案获股东会通过,11月20日股价下跌1.58%
每周股票复盘:东方生物(688298)获多项医疗器械注册证
证券之星 · 11-16
每周股票复盘:东方生物(688298)获多项医疗器械注册证
东方生物(688298)披露获得医疗器械注册证,11月14日股价上涨1.48%
证券之星 · 11-14
东方生物(688298)披露获得医疗器械注册证,11月14日股价上涨1.48%
东方生物(688298.SH)获得医疗器械注册证
智通财经 · 11-14
东方生物(688298.SH)获得医疗器械注册证
每周股票复盘:东方生物(688298)将选举新独立董事
证券之星 · 11-09
每周股票复盘:东方生物(688298)将选举新独立董事
东方生物(688298)披露独立董事候选人提名公告,11月07日股价上涨0.38%
证券之星 · 11-07
东方生物(688298)披露独立董事候选人提名公告,11月07日股价上涨0.38%
东方生物:提名陈军泽先生为公司第三届董事会独立董事候选人
证券日报网 · 11-04
东方生物:提名陈军泽先生为公司第三届董事会独立董事候选人
东方生物(688298)披露拟选举独立董事并调整专门委员会,11月04日股价下跌0.57%
证券之星 · 11-04
东方生物(688298)披露拟选举独立董事并调整专门委员会,11月04日股价下跌0.57%
东方生物(688298.SH)子公司获得医疗器械注册证
智通财经 · 11-04
东方生物(688298.SH)子公司获得医疗器械注册证
每周股票复盘:东方生物(688298)Q3营收增12.26%,净利亏损缩窄55.19%
证券之星 · 11-02
每周股票复盘:东方生物(688298)Q3营收增12.26%,净利亏损缩窄55.19%
东方生物(688298)2025年三季报简析:营收上升亏损收窄,盈利能力上升
证券之星 · 11-01
东方生物(688298)2025年三季报简析:营收上升亏损收窄,盈利能力上升
图解东方生物三季报:第三季度单季净利润同比增长55.19%
证券之星 · 10-30
图解东方生物三季报:第三季度单季净利润同比增长55.19%
东方生物(688298)9月30日股东户数1.33万户,较上期减少3.93%
证券之星 · 10-30
东方生物(688298)9月30日股东户数1.33万户,较上期减少3.93%
东方生物连亏两年半 2020年上市募6.38亿光大证券保荐
中金财经 · 10-15
东方生物连亏两年半 2020年上市募6.38亿光大证券保荐
东方生物(688298.SH)子公司取得两款医疗器械产品注册证书
智通财经 · 09-22
东方生物(688298.SH)子公司取得两款医疗器械产品注册证书
每周股票复盘:东方生物(688298)取消监事会并选举新职工代表董事
证券之星 · 09-21
每周股票复盘:东方生物(688298)取消监事会并选举新职工代表董事
东方生物(688298.SH)子公司获得医疗器械注册证
智通财经 · 09-09
东方生物(688298.SH)子公司获得医疗器械注册证
每周股票复盘:东方生物(688298)回购金额达2788.81万元,拟取消监事会
证券之星 · 09-07
每周股票复盘:东方生物(688298)回购金额达2788.81万元,拟取消监事会
东方生物:累计回购公司股份98.2262万股
证券日报 · 09-01
东方生物:累计回购公司股份98.2262万股
加载更多
公司概况
公司名称:
浙江东方基因生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2020-02-05
主营业务:
浙江东方基因生物制品股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是上游的抗原/抗体、引物、探针、微球等生物原料,中游的免疫诊断平台(胶体金、荧光免疫、酶联免疫)、分子诊断平台(PCR核酸+FISH荧光原位杂交)、流式荧光(液态芯片)平台、生化诊断平台相关的诊断试剂以及配套诊断仪器,下游第三方独立检测实验室等构成,以及动物疫苗、动宠物检测试剂等相关动保产品。
发行价格:
21.25
{"stockData":{"symbol":"688298","market":"SH","secType":"STK","nameCN":"东方生物","latestPrice":24.28,"timestamp":1765436400000,"preClose":24.42,"halted":0,"volume":2015253,"delay":0,"changeRate":-0.0057,"floatShares":202000000,"shares":202000000,"eps":-2.3785,"marketStatus":"已收盘","change":-0.14,"latestTime":"12-11 15:00:00","open":24.41,"high":24.61,"low":24.12,"amount":49017400,"amplitude":0.0201,"askPrice":24.29,"askSize":8,"bidPrice":24.28,"bidSize":17,"shortable":0,"etf":0,"ttmEps":-2.3785,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765503000000},"marketStatusCode":5,"adr":0,"adjPreClose":24.42,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765416600000,1765423800000],[1765429200000,1765436400000]],"highLimit":26.86,"lowLimit":21.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201600000,"isCdr":false,"pbRate":0.77,"roa":"--","roe":"--","epsLYR":-2.69,"committee":0.443787,"marketValue":4895000000,"turnoverRate":0.01,"status":1,"afterMarket":{"amount":0,"volume":0,"close":24.28,"buyVolume":0,"sellVolume":0,"time":1765438437768,"indexStatus":"已收盘 12-11 15:30:00","preClose":24.42},"floatMarketCap":4895000000},"requestUrl":"/m/hq/s/688298","defaultTab":"news","newsList":[{"id":"2585810305","title":"每周股票复盘:东方生物(688298)召开临时股东会并选举独董","url":"https://stock-news.laohu8.com/highlight/detail?id=2585810305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585810305?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:06","pubTimestamp":1763838373,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,东方生物报收于24.85元,较上周的28.08元下跌11.5%。本周,东方生物11月17日盘中最高价报28.39元。公司公告汇总浙江东方基因生物制品股份有限公司于2025年11月20日召开2025年第二次临时股东会,审议通过《关于选举独立董事并调整专门委员会及委员的议案》。本次会议表决结果为同意99,178,155股,反对818,447股,弃权14,149股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2584213011","title":"东方生物(688298)披露选举独立董事并调整专门委员会议案获股东会通过,11月20日股价下跌1.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584213011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584213011?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:25","pubTimestamp":1763648722,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘,东方生物报收于26.2元,较前一交易日下跌1.58%,最新总市值为52.82亿元。该股当日开盘26.68元,最高26.88元,最低26.08元,成交额达5903.86万元,换手率为1.11%。根据公司近日发布的公告,浙江东方基因生物制品股份有限公司于2025年11月20日召开2025年第二次临时股东会,审议通过了关于选举独立董事并调整专门委员会及委员的议案。议案获得普通决议通过,中小投资者对该议案进行了单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2583865189","title":"每周股票复盘:东方生物(688298)获多项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2583865189","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583865189?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:10","pubTimestamp":1763233818,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,东方生物报收于28.08元,较上周的26.15元上涨7.38%。本周,东方生物11月12日盘中最高价报28.99元。本周关注点公司公告汇总:东方生物及控股子公司获多项国内及欧盟医疗器械注册证。公司公告汇总浙江东方基因生物制品股份有限公司及控股子公司杭州莱和生物技术有限公司近日取得多项医疗器械注册证。上述产品注册证有效期均为2025年11月3日至2030年11月2日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK1100","BK1574","BK1222","BK0239","09997","09996","159883","BK1583"],"gpt_icon":0},{"id":"2583502341","title":"东方生物(688298)披露获得医疗器械注册证,11月14日股价上涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502341","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502341?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:31","pubTimestamp":1763130661,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,东方生物报收于28.08元,较前一交易日上涨1.48%,最新总市值为56.61亿元。该股当日开盘27.6元,最高28.53元,最低27.46元,成交额达1.15亿元,换手率为2.03%。公司近日发布公告称,浙江东方基因生物制品股份有限公司及控股子公司杭州莱和生物技术有限公司取得多项医疗器械注册证。上述产品注册证有效期均为2025年11月3日至2030年11月2日。此次取证有助于完善公司在国内外呼吸道检测领域的布局,拓展产品市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK1222","BK1583","688298","BK1574","BK0239","BK1100","09997","159883"],"gpt_icon":0},{"id":"2583207195","title":"东方生物(688298.SH)获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2583207195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583207195?lang=zh_cn&edition=full","pubTime":"2025-11-14 15:44","pubTimestamp":1763106261,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东方生物(688298.SH)发布公告,公司及控股子公司杭州莱和生物技术有限公司(简称“杭州莱和”)近日取得多款医疗器械产品的注册证书。公司上述呼吸道联合检测试剂在国内、欧盟取证,进一步丰富和完善了公司在上述国家和区域的呼吸道专项检测或联检产品布局,拓宽了可销售的产品种类,有利于应对常规季节性呼吸道感染疾病的检测,有利于相关产品国内外市场的整体拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK0239","BK1222","BK1574","09996","688298","159883","BK1100","BK1583"],"gpt_icon":0},{"id":"2582286114","title":"每周股票复盘:东方生物(688298)将选举新独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2582286114","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582286114?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:02","pubTimestamp":1762632145,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,东方生物报收于26.15元,较上周的26.65元下跌1.88%。本周关注点公司公告汇总:东方生物将于2025年11月20日召开临时股东会,审议选举陈军泽为独立董事。董事会提名陈军泽为第三届董事会独立董事候选人,原独立董事李波因个人工作原因辞职。提名委员会同意提名其为独立董事候选人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2581897658","title":"东方生物(688298)披露独立董事候选人提名公告,11月07日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581897658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581897658?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:32","pubTimestamp":1762525950,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,东方生物报收于26.15元,较前一交易日上涨0.38%,最新总市值为52.72亿元。该股当日开盘25.95元,最高26.33元,最低25.9元,成交额达4390万元,换手率为0.83%。公司近日发布公告称,因原独立董事李波因个人工作原因辞职,董事会提名陈军泽为第三届董事会独立董事候选人。陈军泽具备独立董事任职资格,未持有公司股份,与控股股东及主要股东无关联关系。上述议案已提交2025年第二次临时股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2580075384","title":"东方生物:提名陈军泽先生为公司第三届董事会独立董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2580075384","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580075384?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:08","pubTimestamp":1762265280,"startTime":"0","endTime":"0","summary":"证券日报网讯11月4日晚间,东方生物发布公告称,董事会同意提名陈军泽先生为公司第三届董事会独立董事候选人。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-04/doc-infwhekh9771505.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-04/doc-infwhekh9771505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2580786986","title":"东方生物(688298)披露拟选举独立董事并调整专门委员会,11月04日股价下跌0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580786986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580786986?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:31","pubTimestamp":1762248698,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘,东方生物报收于26.23元,较前一交易日下跌0.57%,最新总市值为52.88亿元。该股当日开盘26.39元,最高26.39元,最低26.01元,成交额达5912.62万元,换手率为1.12%。股权登记日为2025年11月13日。会议将审议《关于选举独立董事并调整专门委员会及委员的议案》,并对中小投资者单独计票。出席会议人员包括股东、董事、高管、律师等,相关费用自理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400027715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2580200976","title":"东方生物(688298.SH)子公司获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2580200976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580200976?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:16","pubTimestamp":1762244197,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东方生物(688298.SH)发布公告,公司子公司上海万子健生物科技有限公司及Healgen Scientific LLC(简称“美国衡健”)等多款产品于近期在中国、澳大利亚及新加坡取得医疗器械产品注册证。上述取证产品丰富了公司流式荧光技术平台的产品种类,呼吸道三联检产品扩大了可销售国际市场,有利于相关产品国内外市场的整体拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","09996","159883","BK1100","BK1222","BK1574","BK1583","09997","688298"],"gpt_icon":0},{"id":"2580047157","title":"每周股票复盘:东方生物(688298)Q3营收增12.26%,净利亏损缩窄55.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580047157","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580047157?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:06","pubTimestamp":1762031176,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,东方生物报收于26.65元,较上周的25.12元上涨6.09%。本周,东方生物10月31日盘中最高价报27.6元。业绩披露要点财务报告东方生物2025年三季报显示,前三季度主营收入6.72亿元,同比上升2.16%;归母净利润-2.13亿元,同比上升18.89%;扣非净利润-2.32亿元,同比上升33.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298"],"gpt_icon":0},{"id":"2580417506","title":"东方生物(688298)2025年三季报简析:营收上升亏损收窄,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2580417506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580417506?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:50","pubTimestamp":1761951006,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期东方生物发布2025年三季报。截至本报告期末,公司营业总收入6.72亿元,同比上升2.16%,归母净利润-2.13亿元,同比上升18.89%。本报告期东方生物盈利能力上升,毛利率同比增幅20.02%,净利率同比增幅17.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298"],"gpt_icon":0},{"id":"2579497661","title":"图解东方生物三季报:第三季度单季净利润同比增长55.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579497661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579497661?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:20","pubTimestamp":1761826841,"startTime":"0","endTime":"0","summary":"证券之星消息,东方生物2025年三季报显示,前三季度公司主营收入6.72亿元,同比上升2.16%;归母净利润-2.13亿元,同比上升18.89%;扣非净利润-2.32亿元,同比上升33.71%;其中2025年第三季度,公司单季度主营收入2.69亿元,同比上升12.26%;单季度归母净利润-4953.43万元,同比上升55.19%;单季度扣非净利润-4781.58万元,同比上升66.46%;负债率13.52%,投资收益552.03万元,财务费用-7263.7万元,毛利率41.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298"],"gpt_icon":0},{"id":"2579118635","title":"东方生物(688298)9月30日股东户数1.33万户,较上期减少3.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118635","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118635?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:29","pubTimestamp":1761816540,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东方生物披露,截至2025年9月30日公司股东户数为1.33万户,较6月30日减少543.0户,减幅为3.93%。在医疗器械行业个股中,东方生物股东户数低于行业平均水平,截至9月30日,医疗器械行业平均股东户数为2.21万户。从股价来看,2025年6月30日至2025年9月30日,东方生物区间跌幅为5.48%,在此期间股东户数减少543.0户,减幅为3.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2575081472","title":"东方生物连亏两年半 2020年上市募6.38亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2575081472","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575081472?lang=zh_cn&edition=full","pubTime":"2025-10-15 14:39","pubTimestamp":1760510346,"startTime":"0","endTime":"0","summary":"中国经济网北京10月15日讯 东方生物 2025年半年度报告显示,2025年上半年,公司实现营业收入4.03亿元,同比下降3.62%;归属于上市公司股东的净利润-1.63亿元,上年同期为-1.52亿元;归属于上市公司股东的扣除非经常性损益的净利润-1.84亿元,上年同期为-2.07亿元;经营活动产生的现金流量净额为-1.23亿元,上年同期为-3.32亿元。 东方生物本次发行费用总额为8,668.22万元,其中承销及保荐费用6,060.16万元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/15/20251015489775.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/15/20251015489775.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251015/31708153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0012","BK0239","BK0276","BK0183","BK1564","688298","BK0028","06178","BK1147","601788"],"gpt_icon":0},{"id":"2569042062","title":"东方生物(688298.SH)子公司取得两款医疗器械产品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2569042062","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569042062?lang=zh_cn&edition=full","pubTime":"2025-09-22 16:11","pubTimestamp":1758528692,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东方生物 发布公告,公司控股子公司杭州丹威生物科技有限公司近日取得两款医疗器械产品的注册证书,产品名称分别为:14种高危型人乳头瘤病毒核酸检测及16/18分型试剂盒、新型冠状病毒2019-nCoV及甲型乙型流感病毒核酸联合检测试剂盒。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1583","159883","688298","09997","BK1222","BK1574","BK0239","BK1100"],"gpt_icon":0},{"id":"2569451402","title":"每周股票复盘:东方生物(688298)取消监事会并选举新职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2569451402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569451402?lang=zh_cn&edition=full","pubTime":"2025-09-21 03:23","pubTimestamp":1758396191,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,东方生物报收于26.04元,较上周的27.5元下跌5.31%。同日,选举陈虞女士为公司第三届董事会职工代表董事,任期至第三届董事会任期届满。本次调整后,董事会中兼任高级管理人员及职工代表董事人数未超过董事总数二分之一。公司董事会对张奕东任职期间的勤勉尽责表示感谢。现场出席股东3名,代表股份97,897,767股,网络投票股东94名,代表股份1,938,098股,合计代表股份99,835,865股,占公司有表决权股份总数的52.1622%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2566635698","title":"东方生物(688298.SH)子公司获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2566635698","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566635698?lang=zh_cn&edition=full","pubTime":"2025-09-09 17:14","pubTimestamp":1757409288,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东方生物 发布公告,公司全资子公司Healgen Scientific LLC、控股子公司杭州莱和生物技术有限公司近日取得多款医疗器械产品的注册证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09997","BK1100","159883","688298","09996","BK1222","BK0239","BK1583"],"gpt_icon":0},{"id":"2565543397","title":"每周股票复盘:东方生物(688298)回购金额达2788.81万元,拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2565543397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565543397?lang=zh_cn&edition=full","pubTime":"2025-09-07 04:35","pubTimestamp":1757190912,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘,东方生物报收于27.06元,较上周的27.84元下跌2.8%。回购方案首次披露日为2025年6月28日,实施期限为2025年6月26日至2025年9月25日,预计回购金额为2,500万元至5,000万元,用途为维护公司价值及股东权益。浙江东方基因生物制品股份有限公司董事会2025年9月2日 2025年第一次临时股东大会会议资料浙江东方基因生物制品股份有限公司将于2025年9月15日召开2025年第一次临时股东大会,会议采取现场与网络投票相结合方式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2564432408","title":"东方生物:累计回购公司股份98.2262万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564432408","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564432408?lang=zh_cn&edition=full","pubTime":"2025-09-01 22:09","pubTimestamp":1756735740,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月1日晚间,东方生物发布公告称,公司于2025年6月26日至8月31日期间,通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份98.2262万股,占公司总股本的0.4872%。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-01/doc-infnzezx7581345.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-01/doc-infnzezx7581345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688298","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765443241206,"stockEarnings":[{"period":"1week","weight":-0.029},{"period":"1month","weight":-0.0888},{"period":"3month","weight":-0.1081},{"period":"6month","weight":-0.0476},{"period":"1year","weight":-0.2465},{"period":"ytd","weight":-0.1674}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0065},{"period":"6month","weight":0.155},{"period":"1year","weight":0.1396},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江东方基因生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13289人(较上一季度减少3.93%)","perCapita":"15170股","listingDate":"2020-02-05","address":"浙江省湖州市安吉县递铺街道阳光大道东段3787号","registeredCapital":"20160万元","survey":" 浙江东方基因生物制品股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是上游的抗原/抗体、引物、探针、微球等生物原料,中游的免疫诊断平台(胶体金、荧光免疫、酶联免疫)、分子诊断平台(PCR核酸+FISH荧光原位杂交)、流式荧光(液态芯片)平台、生化诊断平台相关的诊断试剂以及配套诊断仪器,下游第三方独立检测实验室等构成,以及动物疫苗、动宠物检测试剂等相关动保产品。","listedPrice":21.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东方生物(688298)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东方生物(688298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东方生物,688298,东方生物股票,东方生物股票老虎,东方生物股票老虎国际,东方生物行情,东方生物股票行情,东方生物股价,东方生物股市,东方生物股票价格,东方生物股票交易,东方生物股票购买,东方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东方生物(688298)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东方生物(688298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}